Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Tauber

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Clinical Ophthalmology (Auckland, N.Z.)|October 17, 2018
A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye diseaseJoseph Tauber, Barry A Schechter, Jason Bacharach, et al.
Ophthalmology|September 15, 2015
Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 StudyJoseph Tauber, Paul Karpecki, Robert Latkany, et al.
The British Journal of Ophthalmology|February 19, 2016
Scleritis associated with relapsing polychondritisMaite Sainz-de-la-Maza, Nicolas Molina, Luis Alonso Gonzalez-Gonzalez, et al.
Ocular Immunology and Inflammation|October 18, 2013
Clinical features and presentation of posterior scleritis: a report of 31 casesLuis Alonso Gonzalez-Gonzalez, Nicolas Molina-Prat, Priyanka Doctor, et al.
Ophthalmology|October 22, 2011
Scleritis therapyMaite Sainz de la Maza, Nicolas Molina, Luis Alonso Gonzalez-Gonzalez, et al.
Ophthalmology|April 3, 2012
Clinical features and presentation of infectious scleritis from herpes viruses: a report of 35 casesLuis Alonso Gonzalez-Gonzalez, Nicolas Molina-Prat, Priyanka Doctor, et al.
Frontiers in Ophthalmology|November 20, 2024
Perfluorohexyloctane ophthalmic solution for dry eye disease: pooled analysis of two phase 3 clinical trialsAhmad M Fahmy, Jennifer S Harthan, David G Evans, et al.
JAMA Ophthalmology|April 6, 2023
Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease: The ESSENCE-2 Randomized Clinical TrialEsen K Akpek, David L Wirta, Johnathon E Downing, et al.
Ophthalmology|January 13, 2017
Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3)Edward J Holland, Jodi Luchs, Paul M Karpecki, et al.
Eye & Contact Lens|July 29, 2016
Multicenter Study of a Novel Topical Interleukin-1 Receptor Inhibitor, Isunakinra, in Subjects With Moderate to Severe Dry Eye DiseaseMichael H Goldstein, Joseph R Martel, Kenneth Sall, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Clinical Ophthalmology (Auckland, N.Z.)|October 17, 2018
A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye diseaseJoseph Tauber, Barry A Schechter, Jason Bacharach, et al.
Ophthalmology|September 15, 2015
Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 StudyJoseph Tauber, Paul Karpecki, Robert Latkany, et al.
The British Journal of Ophthalmology|February 19, 2016
Scleritis associated with relapsing polychondritisMaite Sainz-de-la-Maza, Nicolas Molina, Luis Alonso Gonzalez-Gonzalez, et al.
Ocular Immunology and Inflammation|October 18, 2013
Clinical features and presentation of posterior scleritis: a report of 31 casesLuis Alonso Gonzalez-Gonzalez, Nicolas Molina-Prat, Priyanka Doctor, et al.
Ophthalmology|October 22, 2011
Scleritis therapyMaite Sainz de la Maza, Nicolas Molina, Luis Alonso Gonzalez-Gonzalez, et al.
Ophthalmology|April 3, 2012
Clinical features and presentation of infectious scleritis from herpes viruses: a report of 35 casesLuis Alonso Gonzalez-Gonzalez, Nicolas Molina-Prat, Priyanka Doctor, et al.
Frontiers in Ophthalmology|November 20, 2024
Perfluorohexyloctane ophthalmic solution for dry eye disease: pooled analysis of two phase 3 clinical trialsAhmad M Fahmy, Jennifer S Harthan, David G Evans, et al.
JAMA Ophthalmology|April 6, 2023
Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease: The ESSENCE-2 Randomized Clinical TrialEsen K Akpek, David L Wirta, Johnathon E Downing, et al.
Ophthalmology|January 13, 2017
Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3)Edward J Holland, Jodi Luchs, Paul M Karpecki, et al.
Eye & Contact Lens|July 29, 2016
Multicenter Study of a Novel Topical Interleukin-1 Receptor Inhibitor, Isunakinra, in Subjects With Moderate to Severe Dry Eye DiseaseMichael H Goldstein, Joseph R Martel, Kenneth Sall, et al.
Pageof 4